Exploring the Relationship Between Efpeglenatide Dose and Cardiovascular Outcomes in Type 2 Diabetes: Insights From the AMPLITUDE-O Trial

Post time 2023-3-10 00:04:05

journal：Circulation

Authors：Hertzel C. Gerstein; Zhuoru Li; Chinthanie Ramasundarahettige; Seungjae Baek; Kelley R.H. Branch; Stefano Del Prato; Carolyn S.P. Lam; Renato D. Lopes; Richard Pratley; Julio Rosenstock; Naveed Sattar

Published date：--

DOI：10.1161/circulationaha.122.063716

Article link：http://dx.doi.org/10.1161/circulationaha.122.063716

Article Source：Ovid Technologies (Wolters Kluwer Health)。

Remark：

Post time 2023-3-10 00:04:06

: This post has been completed
Completed attachments will be deleted within 24 hours.

Post time 2023-3-10 00:08:52

: This post has been completed
Completed attachments will be deleted within 24 hours.

Post time 2023-3-10 00:57:37

: This post has been completed
Completed attachments will be deleted within 24 hours.

[AHA] Exploring the Relationship Between Efpeglenatide Dose and Cardiovascular Outcomes in Type 2 Diabetes: Insights From the AMPLITUDE-O Trial

Best Answer

Same Category

Latest Reply

Announcement

Enthusiastic users today